Bangkok Genomics Innovation Public Company Limited provides medical analysis services in Thailand. The company offers screening for fetal chromosomal abnormalities using non-invasive prenatal testing under the NIFTY brand; preimplantation chromosomal abnormality and thalassemia carrier gene screening; infectious disease group analysis; testing for human papilloma virus; and monkeypox virus, COVID-19 Pathogen, and COVID-19 pathogen immunity testing. It also provides other screening tests, such as cancer-related gene screening to predict the risk of inherited cancer, to monitor treatment and select drugs that are appropriate for one's genetics, and to provide treatment and disease prevention. In addition, the company offers analysis that can decode individual genetics for planning life in terms of diet, exercise, risk of various genetic diseases, and application to the science of anti-aging; newborn screening; and health check-ups for various needs. Further, it supports research services in both medical and other fields; offers DNA and RNA sequencing; metabolomics and proteomics services; and medical products comprising of genetic sequencer, total solutions, real-time PCR, and cell-free DNA storage tube. The company serves government sectors such as medical schools, health centers, and private sectors such as clinics, hospitals, private medical laboratories, leading research institutes and universities. Bangkok Genomics Innovation Public Company Limited was founded in 2017 and is headquartered in Bangkok, Thailand.